Gene Therapy Vector and Delivery Development
A gene therapy programme depends on more than the therapeutic sequence alone. Vector architecture, tissue tropism, expression control, delivery efficiency and biological activity must be considered together from the earliest stages of development. Creative Biolabs provides customised research services for viral and non-viral gene delivery programmes, supporting projects from construct design through in vitro characterisation and preclinical evaluation.
Services can be commissioned individually or combined into a coordinated development plan based on the disease indication, target tissue, therapeutic cargo and intended route of administration.
Therapeutic construct and expression cassette design
Creative Biolabs supports the design and optimisation of expression constructs for gene replacement, gene silencing, genome editing and other genetic therapeutic strategies.
Development considerations may include promoter selection, coding-sequence optimisation, untranslated regions, regulatory elements and vector-specific packaging constraints. The design process also considers the required duration and level of expression, target cell type and potential effects of the selected regulatory components.
Constructs can be evaluated in relevant cell systems to confirm transgene expression and biological function before progressing to vector production or further optimisation.
Viral vector development
Viral vectors offer efficient gene transfer but differ in packaging capacity, tropism, expression profile and immunological properties. Creative Biolabs provides development support for adeno-associated virus, lentiviral, adenoviral and other vector systems.
Projects may include vector and capsid selection, plasmid construction, vector production, purification and analytical characterisation. Depending on the platform, testing may cover vector genome titre, particle concentration, transducing or infectious activity, identity, purity and residual process-related components.
Vector performance can be compared across relevant cell types to assess transduction efficiency, transgene expression and functional activity. Capsid or vector engineering strategies may also be explored when improved tissue targeting or delivery performance is required.
Non-viral delivery development
For programmes that require alternatives to viral vectors, Creative Biolabs develops lipid-, polymer- and nanoparticle-based delivery systems for nucleic acid cargoes. These may include plasmid DNA, messenger RNA, small interfering RNA and gene-editing components.
Formulation studies can evaluate particle size, distribution, surface charge, encapsulation efficiency, cargo protection, release behaviour and storage stability. Cellular studies may assess uptake, intracellular trafficking, endosomal escape, expression or editing activity and cytotoxicity.
Delivery systems can be modified with targeting ligands or other surface components when preferential uptake by a selected cell or tissue type is an important development objective.
Gene-editing delivery
Efficient delivery remains a central challenge for CRISPR-based research. Creative Biolabs supports the delivery of plasmid DNA, RNA and ribonucleoprotein gene-editing components using viral or non-viral systems.
Studies may include guide RNA design, donor-template strategy, delivery optimisation, and measurement of editing efficiency. Relevant assays can also assess on-target modification, selected off-target sites, cell viability and the resulting molecular or cellular phenotype.
Preclinical characterisation
Candidate vectors and delivery systems can progress to preclinical studies designed to examine biological activity, biodistribution, expression kinetics, pharmacology and safety-related endpoints. Study design is tailored to the vector type, cargo, target tissue and disease model.
By connecting construct design, vector development, delivery optimisation, and functional testing, Creative Biolabs helps research teams compare candidates using consistent experimental criteria and generate data for informed development decisions.
Contact Creative Biolabs to discuss a gene therapy vector or delivery development programme.
